Abstract: The invention disclosed herein relates to a composition and method of reducing the joint pain associated with hemarthrosis or hemophilic arthropathy. The method includes administering a COX-2 inhibitor, such as rofecoxib, celecoxib, valdecoxib, etoricoxib or other “coxib” drug which is encapsulated in PLGA micro-particles. The COX-2 inhibitor can be administered directly to an area where pain exists by an injection device. In a preferred embodiment, rofecoxib or celecoxib can be encapsulated in PLGA micro-particles for controlled, sustained release over a 2-8-week period. The non-systemic delivery and the controlled, sustained release of rofecoxib alleviate the cardiovascular side effects associated with systemic rofecoxib treatments.

Abstract: A medicament set adapted to regulate multiple receptors simultaneously in patients experiencing diabetic peripheral neuropathy pain, the medicament set comprising: at least three distinct and separate medicaments for treating diabetic peripheral neuropathy pain, the at least three medicaments being a first medicament for treating peripheral neuropathy pain, being formulated for clinical administration as a locally injectable medicament using an injection device, and comprising polylactic glycolic acid (PLGA) micro-particles being loaded with a sodium channel blocker and local anesthetic drug, a second medicament for treating peripheral neuropathy pain, being formulated for clinical administration as a locally injectable medicament using an injection device, and comprising PLGA micro-particles being loaded with a sodium channel blocker and anti-convulsant drug, and a third medicament for treating peripheral neuropathy pain, being formulated for clinical administration as a locally injectable medicament using a

Abstract: Provided herein are methods and compositions for treatment of a patient having a wound resulting from surgical resection of a tumor mass. In some embodiments, the methods provided herein include administering to the entirety of the wound area a composition before the wound area is closed, the composition having a first plurality of micro-particles comprising PLGA and one or more cancer treatment drugs, and a second plurality of micro-particles comprising PLGA and one or more wound healing drugs; wherein the wound healing drugs are released for a first period of time and the cancer treatment drugs are released for a second period of time without an initial burst release.

Abstract: A medicament set adapted to regulate multiple receptors simultaneously in patients experiencing diabetic peripheral neuropathy pain, the medicament set comprising: at least three distinct and separate medicaments for treating diabetic peripheral neuropathy pain, the at least three medicaments being a first medicament for treating peripheral neuropathy pain, being formulated for clinical administration as a locally injectable medicament using an injection device, and comprising polylactic glycolic acid (PLGA) micro-particles being loaded with a sodium channel blocker and local anesthetic drug, a second medicament for treating peripheral neuropathy pain, being formulated for clinical administration as a locally injectable medicament using an injection device, and comprising PLGA micro-particles being loaded with a sodium channel blocker and anti-convulsant drug, and a third medicament for treating peripheral neuropathy pain, being formulated for clinical administration as a locally injectable medicament using a

Abstract: The invention disclosed herein relates to a composition and method of reducing the joint pain associated with hemarthrosis or hemophilic arthropathy. The method includes administering a COX-2 inhibitor, such as rofecoxib, celecoxib, valdecoxib, etoricoxib or other “coxib” drug which is encapsulated in PLGA micro-particles. The COX-2 inhibitor can be administered directly to an area where pain exists by an injection device. In a preferred embodiment, rofecoxib or celecoxib can be encapsulated in PLGA micro-particles for controlled, sustained release over a 2-8-week period. The non-systemic delivery and the controlled, sustained release of rofecoxib alleviate the cardiovascular side effects associated with systemic rofecoxib treatments.